PDCD1 and breast cancer: One study demonstrated that a PD-1 inhibitor, nivolumab, improved the cytotoxic activity of OCT4 and SOX2 CTLs, suggesting a potential therapeutic approach for BC stem-like cells (BCSCs) in drug-resistant BC models, both in vitro and in vivo [179].